Last edition
News about "EMA marketing authorisation application"
Pfizer and Valneva's Lyme Vaccine Candidate Gets EMA Review Validation
Pfizer and Valneva’s Lyme disease vaccine candidate receives validation from the European Medicines Agency (EMA), supported by more than 70 percent efficacy in the phase 3 VALOR trial.
EMA Marketing Authorisation Application | 14/08/2026 | By News Bureau
Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.
EMA Marketing Authorisation Application | 07/05/2026 | By News Bureau | 136
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy